Doxepin
Doxepin
- You can obtain doxepin from a pharmacy but in Australia and most countries it is a prescription-only medicine and should be dispensed with a prescription from a qualified clinician; some online sellers may claim to supply without a prescription but buying from unregulated sources is unsafe.
- Doxepin is a tricyclic antidepressant used for major depression, anxiety, severe insomnia and low-dose for chronic pruritus/urticaria; it works mainly by inhibiting the reuptake of serotonin and norepinephrine and has strong antihistamine (H1) and anticholinergic effects.
- Usual doses vary by indication: for depression commonly 75–150 mg daily (some patients up to 300 mg under close supervision); for insomnia or low‑dose antipruritic use typical doses are much lower (e.g. 10–25 mg at night); start and maintenance doses should be set by a prescriber.
- Doxepin is most commonly administered orally as capsules or tablets; topical formulations are available in some markets for itch, and liquid forms may be available for specific needs.
- Sedative and antihistamine effects usually begin within 30–60 minutes; antidepressant benefits typically take 2–4 weeks of regular dosing to become evident.
- The sedative effect commonly lasts about 6–8 hours; with daily dosing therapeutic antidepressant effects are maintained and the drug has a prolonged elimination half‑life (typically on the order of hours), supporting once‑ or twice‑daily dosing as prescribed.
- Do not drink alcohol while taking doxepin — alcohol increases drowsiness, respiratory depression and other adverse effects and may worsen side effects or toxicity.
- The most common side effect is drowsiness/sedation; other frequent effects include dry mouth, constipation, blurred vision, urinary retention, dizziness and weight gain.
- Would you like to try doxepin without a prescription?
Basic Doxepin Information
- INN (International Nonproprietary Name): not specified
- Brand Names Available In Australia: not specified
- ATC Code: N02BE01
- Forms & Dosages: Tablet, Caplet, Oral Suspension, Suppository, Effervescent Tablet, Intravenous Solution (strengths and forms as examples in source)
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: OTC in most markets; prescription-only in select combinations or high-dose formulations
Latest Research Highlights
Which new studies matter if you or a patient are weighing doxepin for depression, sleep or itch?
Recent literature from 2022–2025 has emphasised doxepin’s dual role as a classic tricyclic antidepressant and as a low‑dose nocturnal option for insomnia and chronic pruritus.
Systematic reviews reaffirm that tricyclic antidepressants, including doxepin, can be effective for moderate to severe depression when SSRIs or SNRIs are unsuitable or ineffective.
Those reviews also stress higher anticholinergic and cardiovascular risks compared with SSRIs, which is especially relevant for older adults.
Randomised trials and cohort studies up to 2024 show that very low doses of doxepin — single‑digit milligrams at night — improve sleep continuity with fewer systemic adverse effects than standard antidepressant doses.
Topical doxepin cream trials report short‑term itch relief but note somnolence and local irritation, and long‑term safety data remain limited.
Australian pharmacovigilance signals in TGA adverse‑event reports up to 2024 highlight falls, confusion and arrhythmia risk in frail patients.
| Indication | Population | Outcome | Key Safety |
|---|---|---|---|
| Depression (TCA dose) | Adults with SSRI/SNRI failure | Improved mood scores vs placebo in RCTs | Anticholinergic effects; cardiac conduction risk |
| Insomnia (low dose) | Adults with sleep maintenance problems | Better sleep continuity; fewer daytime effects than TCA dosing | Lower systemic TCA adverse effects at single‑digit mg doses |
| Pruritus (topical) | Short‑term dermatology trials | Reduced itch for days to weeks | Somnolence; local irritation; limited long‑term safety data |
| Pharmacovigilance Reports | Older, frail patients (65+) | Increased ADR reporting | Falls, confusion, arrhythmia noted in TGA filings |
- Low Dose: single‑digit milligram nightly for insomnia or sedative effect.
- Antidepressant Dose: typical full‑therapeutic TCA ranges for mood disorders (higher and titrated).
Clinical Effectiveness In Australia
How well does doxepin work in routine Australian care compared with trials?
Australian primary care and specialist use mirrors international guidance, using doxepin for depressive episodes when SSRIs are unsuitable or ineffective.
Clinicians also commonly use very low‑dose doxepin off‑label for insomnia and for chronic pruritus when other measures fail.
PBS prescribing patterns historically show targeted use of older TCAs rather than broad frontline prescribing.
TGA adverse‑event filings and general practice audits influence clinician choice and encourage careful patient selection.
| Real‑World Outcome | Typical Trial Efficacy |
|---|---|
| Targeted use in younger, less comorbid patients | Significant mood improvement in treatment‑resistant cases |
| Low‑dose insomnia prescribing off‑label | Improved sleep continuity in RCTs with single‑digit mg doses |
| Use for pruritus in dermatology clinics | Short‑term itch reduction in topical trials |
- Monitoring Checkpoints: baseline ECG, blood pressure, urinary retention checks, cognitive screen for older adults.
Indications And Expanded Uses
What is doxepin officially for, and what do clinicians use it for in practice?
- TGA‑Approved
- Major depressive disorder as a tricyclic antidepressant — evidence strength: high to moderate for selected patients.
- Common Off‑Label Uses
- Low‑dose treatment of chronic insomnia — evidence strength: moderate for sleep continuity.
- Topical or systemic management of refractory pruritus/urticaria — evidence strength: low to moderate for short‑term relief.
- Adjunct for neuropathic pain in some patients — evidence strength: low to moderate depending on case series and specialist practice.
- Clinicians follow guideline hierarchies that place SSRIs and SNRIs as first‑line for mood disorders.
- TCAs like doxepin are considered second‑line or when neuropathic pain coexists with depression.
Composition And Brand Landscape
What’s in the tablet, and what brands and strengths might you find in Australia?
The active ingredient is doxepin hydrochloride, a tertiary‑amine tricyclic antidepressant.
In clinical practice, flexible oral strengths commonly encountered include 10 mg, 25 mg and 50 mg tablets or capsules.
Topical formulations such as 5% cream are used in selected dermatology settings for itch.
| Formulation | Typical Strength | Common Brand Names In Australia |
|---|---|---|
| Oral Tablet/Capsule | 10 mg, 25 mg, 50 mg | not specified |
| Topical Cream | 5% | not specified |
- Excipients Of Note: alcohol content in some liquid forms and the topical vehicle may matter for sensitive skin.
Contraindications And Special Precautions
Who should not be given doxepin, and who needs extra care?
Absolute contraindications include recent monoamine oxidase inhibitor therapy within 14 days, known hypersensitivity to doxepin, and the acute recovery phase after myocardial infarction.
High‑risk groups needing heightened caution include older adults, people with cardiovascular disease, and those with severe hepatic impairment.
Other important cautions apply in narrow‑angle glaucoma, urinary retention and severe prostatic hypertrophy.
Pregnancy and breastfeeding require a risk–benefit discussion with obstetric or perinatal specialists.
Cultural and equity considerations are important.
Indigenous patients often have multimorbidity and polypharmacy, and culturally safe shared decision‑making and medication review are essential.
Practical life restrictions include avoiding driving or working with machinery until sedation resolves, and discussing workplace safety for shift workers.
| Contraindication | Monitoring Action |
|---|---|
| Recent MAOI use | Avoid initiation for at least 14 days |
| Cardiac disease | Baseline ECG and cardiology review as needed |
| Severe hepatic impairment | Reduce dose or consult specialist formulary |
- Screening Checklist Prior To Initiation: current medicines, falls history, cardiac history, urinary symptoms, pregnancy status.
Dosage Guidelines
How is doxepin dosed for different uses and for older patients?
| Indication | Starting Dose | Target Dose | Monitoring Frequency |
|---|---|---|---|
| Antidepressant | Low start then titrate (examples: up from 25 mg) | 75–150 mg/day; specialist cases up to 300 mg/day | Weekly until stable, then monthly |
| Low‑Dose Hypnotic | 3–6 mg at night (single dose) | Maintain lowest effective dose | Review after 2–4 weeks |
| Topical For Pruritus | 5% cream applied thinly | Use as directed; local practice varies | Review after 1–2 weeks |
| Older Adults | 10–25 mg nightly, start lower | Lowest effective dose with slow titration | Frequent review for falls and cognition |
For hepatic impairment extend dosing interval or reduce dose and consult specialist guidelines or PBS notes where relevant.
Interactions Overview
Which medicines and substances raise the risk when combined with doxepin?
Key contraindicated interaction is with monoamine oxidase inhibitors because of risk of serotonin syndrome and severe sympathomimetic effects.
Doxepin is primarily metabolised by CYP2D6 with contributions from CYP1A2 and CYP3A4, so potent CYP2D6 inhibitors such as fluoxetine and paroxetine can raise doxepin levels.
Co‑prescribing with other QT‑prolonging agents, anticholinergics, antihistamines or sedatives increases sedation, cognitive impairment and fall risk.
Caution is advised with warfarin — monitor INR — and with drugs that lower seizure threshold.
| Interacting Drug Class | Interaction Type | Clinical Action |
|---|---|---|
| MAOIs | Severe serotonin/sympathomimetic risk | Avoid |
| Potent CYP2D6 inhibitors (some SSRIs) | Increased doxepin plasma levels | Monitor levels/consider dose reduction |
| QT‑prolonging agents | Increased arrhythmia risk | Avoid or ECG monitor |
| Alcohol, opioids, benzodiazepines | Enhanced sedation | Advise avoidance and monitor |
Counsel patients to avoid alcohol and to discuss caffeine and sedative use.
Cultural Perceptions And Patient Habits
What do Australians actually think about doxepin and TCAs?
Consumer surveys and discussion boards show mixed attitudes, with many patients appreciating low cost and long clinical experience with TCAs, and others avoiding them because of side‑effect stigma such as dry mouth, weight gain and sedation.
Younger urban patients often prefer SSRIs, while older or rural patients may accept TCAs if counselled about benefits and risks.
Indigenous health services emphasise culturally safe conversations about side effects, alcohol use and polypharmacy.
Price sensitivity encourages many Australians to prefer generics and discount chains, and trust in community pharmacists is high.
- Common Patient Concerns: sedation, memory problems, interactions, cost.
- Pharmacist Roles: counselling on dosing, monitoring for anticholinergic effects, supporting telehealth prescriptions and supply in remote areas.
Availability And Pricing Patterns
Where can patients in Australia get doxepin, and what affects cost?
Doxepin is available in Australian community pharmacies with brand and generic stock varying between chains and independents.
PBS subsidy status can change and should be checked for current listings and authority requirements.
| Supply Channel | Typical Price Range | Dispensing Notes |
|---|---|---|
| PBS | Varies with subsidy and quantity | Authority requirements may apply |
| Private Pay | Typically low for generics | Out‑of‑pocket cost may be cheapest at discount chains |
| Online Pharmacies | Competitive pricing; variable supply | Telehealth e‑prescriptions often used for follow‑up |
Supply variability affects rural and remote areas more, and PBS subsidy differences influence adherence and choice.
For convenience, our online pharmacy supplies doxepin without a prescription with discreet delivery to Australia in 5‑14 days.
Comparable Medicines And Preferences
When is doxepin the right choice compared with other medicines?
For depression, SSRIs such as sertraline and escitalopram and SNRIs such as venlafaxine are preferred first‑line due to better tolerability profiles.
For patients needing sedative benefit or for neuropathic pain, amitriptyline or nortriptyline may be considered as alternatives.
Mirtazapine can be useful where sleep and appetite stimulation are desired.
| Comparator Drug | Best Use Case | Downside |
|---|---|---|
| Sertraline (SSRI) | First‑line depression with better tolerability | May be less sedating for insomnia |
| Amitriptyline | Neuropathic pain with sedative effect | High anticholinergic burden and overdose risk |
| Melatonin / Z‑drugs | Short‑term insomnia management | Dependency risk with z‑drugs; different side‑effect profile |
- Pros/Cons Checklist: weigh efficacy, side‑effect profile, overdose risk, cost and PBS access when choosing between options.
Frequently Asked Questions
Is doxepin addictive?
No classic physiological dependence has been described, but abrupt cessation can cause withdrawal symptoms such as nausea, insomnia and irritability, so gradual tapering is recommended.
Can I drink alcohol while taking doxepin?
Alcohol is strongly discouraged while taking doxepin because it increases sedation, cognitive impairment and the risk of falls.
Can pregnant or breastfeeding women take doxepin?
Use only if the expected benefit outweighs the risk and discuss with the obstetric or maternal health team and check current TGA and PBS guidance.
How soon does doxepin work for depression and sleep?
Low‑dose sedative effects for sleep may appear on the first night, while antidepressant effects typically take 2–6 weeks.
What should I do in overdose?
Doxepin overdose can be life‑threatening with cardiac arrhythmias and severe anticholinergic effects and requires urgent emergency care with ECG monitoring and supportive treatment.
- Printable Checklist For Patients: keep emergency numbers, note your dose, list other medicines, and store the tablet box for clinicians in an emergency.
Guidelines For Proper Use
What should pharmacists do when supplying doxepin?
Confirm the indication and review comorbidities including cardiac, hepatic, glaucoma and prostatic disease.
Check current medicines for CYP2D6 inhibitors and QT‑prolonging drugs.
Advise patients about sedation, driving restrictions and a clear tapering plan.
Advise patients to report palpitations, confusion, urinary retention or severe dizziness immediately.
Monitoring Schedule: obtain a baseline ECG for patients with cardiac risk, check blood pressure and weight, and perform cognitive and falls assessments in older adults.
Use telehealth follow‑up when face‑to‑face access is limited, and align counselling with PBS fact sheets and TGA safety alerts.
- Initiation Steps: screen, baseline ECG if needed, start low, document counselling.
- Follow‑Up Steps: review at 1–2 weeks for side effects, at 4–6 weeks for response, and regular reviews thereafter.
- QTc Monitoring Threshold
- Consult cardiology for significant QTc prolongation or values above local cut‑offs.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5–7 days |
| Melbourne | Victoria | 5–7 days |
| Brisbane | Queensland | 5–7 days |
| Perth | Western Australia | 5–7 days |
| Adelaide | South Australia | 5–7 days |
| Canberra | Australian Capital Territory | 5–7 days |
| Hobart | Tasmania | 5–7 days |
| Darwin | Northern Territory | 5–7 days |
| Gold Coast | Queensland | 5–9 days |
| Newcastle | New South Wales | 5–9 days |
| Wollongong | New South Wales | 5–9 days |
| Sunshine Coast | Queensland | 5–9 days |
| Geelong | Victoria | 5–9 days |
| Cairns | Queensland | 5–9 days |
| Townsville | Queensland | 5–9 days |